The eye is the window to the brain

ViewMind uses ocular digital phenotyping, virtual reality, and artificial intelligence to evaluate brain health, providing the most precise measurements of 16 cognitive domains and 19 related brain regions.

Scientific partnerships:

ViewMind difference

Precision Advantage

ViewMind’s patented technology is based on fundamental scientific research performed over 20 years under the leadership
of ViewMind’s Chief Science Officer, Gerardo Fernandez PhD

Dr. Fernandez conducted research at some of the world’s leading institutions, including in Argentina, the United Kingdom, the United States, and Germany.


ViewMind technology shows remarkable accuracy, as evidenced in 25 peer-reviewed publications and supported by clinical data on thousands of patients studied across four continents in scores of clinical trials, including a 4-year longitudinal study and studies in familial populations.

Published studies:

Clinical studies
conducted or in progress:



Memory-driven eye movements prospectively predict dementia in people at risk of Alzheimer’s disease

Mario Parra, Juan Granada, Gerardo Fernandez


Alzheimers Dement (Amst), 2022


The eye as a biomarker for Alzheimer's disease: oculomotor behaviours yield a novel digital biomarker for preclinical risk detection

Fernandez, Gerardo and Mendez, Luis and Lopera, Francisco and Fernandez, Gerardo and Mendez, Luis and Lopera, Francisco and Parra Rodriguez, Mario

Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, 2022

Oculomotor abnormalities in offspring of late-onset Alzheimer’s disease

Fernandez G, Gonzalez AP, Abulafia C, Fiorentini L, Agamennoni O, Guinjoan S.

Current Alzheimer Research, 2022

Oculomotor Behaviors and Integrative Memory Functions in the Alzheimer’s Clinical Syndrome

Fernandez Gerardo & Parra Mario

Journal of Alzheimer’s disease, 2021

How it works

ViewMind gathers and analyzes eye movement patterns to produce accurate, AI-powered results

Traditional neuropsychological assessment tests are primarily concerned with behavioral response. Is the provided answer correct or incorrect? The majority of the cognitive decision-making signal is disregarded.


ViewMind’s technology analyzes every cognitive processing step based on eye-movement responses to visual stimuli. The signal fidelity is over a million times greater than traditional assessments. ViewMind employs Ocular Digital Phenotyping using context-aware artificial intelligence to assess the status of 16 cognitive domains and 19 related brain regions. In the second analysis stage, the phenotypes of neurodegenerative diseases have been derived and validated in collaboration with some of the world’s leading expert clinicians and researchers.


ViewMind measures eye-movement responses to visual stimuli using VR headsets that are more accurate compared to separate camera sensors. They also provide a clinically controlled environment. Eye movement patterns change precisely and repeatedly based on alterations in cognition, like fingerprints, so having the most sensitive instrument for these measurements is key.

Group 10760

Virtual reality headset

VR headset enables ViewMind to conduct an analysis of eye movement in a controlled environment, using high-fidelity equipment for the most accurate results.
Group 10761

Eye movement assessment

ViewMind tracks reproducible phenotypic eye movement patterns to reveal the state of cognitive domains and related brain regions.
Group 10762

AI-based analysis

ViewMind’s patented software identifies minor deviations in oculomotor patterns, quantifies them, and correlates them with the eye patterns of specific pathologies and neurocognitive functions.

ViewMind Industry Applications

Pharmaceutical companies

Pre-screen prospective study participants with a scalable, non-invasive solution. Cognitively match cohorts. Measure the impact of new drugs on cognitive health.

Healthcare institutions

Assess and monitor patients’ brain health. Measure the impact of treatments on their neurocognitive resources.